日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Eli Lilly plans to introduce its weight loss drug in China soon

By Zhou Wenting | chinadaily.com.cn | Updated: 2024-12-06 19:24
Share
Share - WeChat
The booth of US pharmaceutical company Eli Lilly and Co at the seventh China International Import Expo held in Shanghai in November 2024. [Photo provided to chinadaily.com.cn]

The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its innovative weight loss therapy available to patients in China very soon.

"At Lilly, we're committed to supporting individuals affected by obesity, which is a chronic disease that requires effective treatment options and long-term management," said Huzur Devletsah, president and general manager of Lilly China.

Her comment came after Lilly announced the top-line results from the SURMOUNT-5 clinical trial that day, showing that its Zepbound (tirzepatide) provided a 47 percent greater relative weight loss compared to Wegovy (semaglutide) by Danish pharmaceutical company Novo Nordisk.

Wegovy was marketed earlier than Zepbound, and is currently the world's best-selling GLP-1 weight loss medicine.

Lilly said the trial results showed that on average, Zepbound led to a weight loss of 20.2 percent compared to 13.7 percent with Wegovy. A key competitiveness of Zepbound lies in that it is the only US FDA-approved product that activates both GLP-1 and GIP - two receptors playing key roles in regulating blood sugar and energy balance in the human body.

GLP-1 therapies, originally used to treat type 2 diabetes, have gained popularity throughout the world due to their weight loss effect in recent years. Novo Nordisk and Lilly are currently the main global leaders.

The companies' financial reports showed that in the first three quarters of this year, Wegovy's revenue was about $5.53 billion, a year-on-year increase of 77 percent, and Zepbound's revenue was nearly $3.02 billion after the figure exceeded $1 billion for the first time in the second quarter.

British bank Barclays predicted that the global weight loss therapy market will grow to $150 billion by 2030. And according to the forecast of US consultancy Frost & Sullivan, the market size of GLP-1 medicines in China will exceed 50 billion yuan in 2030.

Domestic medical experts said that such positive trial results may affect doctors' drug recommendations in clinical use, but which therapies to prescribe may be affected by multiple factors, including indications, prices, reimbursement policies, and patient preferences.

In October, Lilly announced a roughly $200 million expansion of its manufacturing site in Suzhou, Jiangsu province, aiming to increase production of such innovative medicines.

During a previous interview with media outlet ThePaper.cn, Zhou Xiaping, global senior vice-president of Novo Nordisk and president of Novo Nordisk China, said that with full confidence in its products, the company welcomes healthy competition in the field of GLP-1 medicines to jointly help more obese patients.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 男女啪啪片 | 亚洲国产精品99久久久久久久久 | 久色激情| 国产乱码精品一区二区三区五月婷 | 亚洲欧洲在线视频 | 国产中文字幕一区 | 午夜久久 | 亚洲国产精品久久综合 | 久草久草视频 | 亚洲午夜在线视频 | 成人精品一区 | 欧美一区二区三区四区视频 | 天天干精品 | 91在线视频免费观看 | 免费在线成人 | 久草在线视频资源站 | 香蕉视频99| 26uuu在线| 成人免费毛片高清视频 | 欧美日韩中文在线观看 | 超碰在线影院 | 国产精品日韩在线观看 | 欧美日韩成人网 | 日本大片在线观看免费视频 | hdfreexxxx中国妞 | 久久99精品久久久久久臀蜜桃 | wwwxx免费 | 九二淫黄大片看片 | 欧美在线a| 夜夜撸夜夜爽 | 999成人网 | 99爱在线观看 | 99精品视频在线视频免费观看 | 欧美日韩国产一区二区三区伦 | 欧美黄视频网站 | 欧美日韩一区二区三区免费视频 | 色综合天天综合网国产成人 | 免费在线小视频 | 亚洲成人网在线观看 | 亚洲精品久久久久中文字幕欢迎你 | 天天爱天天做天天干 |